Silk Road Medical, Inc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Charles S. McKhann
- Full Time Employees
- 474
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1213 Innsbruck Drive Sunnyvale CA United States of America 94089
- IPO Date
- Apr 4, 2019
- CIK
- 0001397702
- Website
- silkroadmed.com
- Similar Companies
- Business
- Silk Road Medical, Inc. Silk Road Medical, Inc. (Nasdaq: SILK) develops and commercializes minimally invasive medical devices focused on reducing stroke risk in patients with carotid artery disease through its proprietary TransCarotid Artery Revascularization (TCAR) platform, which combines neuroprotection principles with endovascular techniques; core products include the ENROUTE Transcarotid Neuroprotection System for temporary blood flow reversal and common carotid artery access, ENROUTE Transcarotid Stent System as a self-expanding self-tapering stent for plaque stabilization, ENHANCE Transcarotid Peripheral Access Kit for initial arterial access, ENROUTE 0.014 Guidewire for lesion navigation, and ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter for post-stent dilatation. The company, founded in 2007 and headquartered in Sunnyvale, California, with manufacturing facilities in Sunnyvale and Plymouth, Minnesota, primarily serves vascular specialists and hospitals in the United States through a direct sales force of area managers and clinical support specialists, targeting patients with narrowed or blocked carotid arteries that contribute to one-third of all strokes. In September 2024, Silk Road Medical became a wholly-owned subsidiary of Boston Scientific Corporation Boston Scientific Corporation following the latter's $1.26 billion acquisition at $27.50 per share, integrating the exclusive TCAR product suite into Boston Scientific's vascular portfolio to expand commercial reach and enhance stroke prevention offerings amid projected 2024 net revenue of $194-198 million.
Boston Scientific Announces Results for Third Quarter 2024
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY and SILK on Behalf of Shareholders
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger of Silk Road Medical, Inc.
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. – SILK
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. - SILK
SILK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Silk Road Medical to Boston Scientific
SILK ROAD MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silk Road Medical, Inc. - SILK
Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Silk Road Medical, Inc.
Shareholder Alert: Ademi LLP investigates whether Silk Road Medical, Inc. has obtained a Fair Price for its Public Shareholders
Silk Road Medicine Rockets On Boston Scientific's $1.16 Billion Takeover
Boston Scientific Adds Stroke Prevention To Vascular Portfolio Via Silk Road Medical's $1.3B Deal
Why Is Silk Road Medical (SILK) Stock Up 24% Today?
Breaking News: Is Silk Road Medical's $27.50 Per Share Sale Price a Fair Deal? Johnson Fistel, LLP Investigates Deal Terms